SCHEMBL6509462

SCHEMBL6509462

NC(=O)CCSc1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1.O=c1[nH]ccc2c3[nH]c(Sc4cnoc4)nc3c3ccc(F)cc3c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 11/20 0.43
CHEK1 O14757 4/20 0.43
JAK3 P52333 3/20 0.43
JAK1 P23458 2/20 0.43
TYK2 P29597 2/20 0.43
IKBKB O14920 1/20 0.43
MAPK13 O15264 1/20 0.43
DAPK3 O43293 1/20 0.43
PRKD3 O94806 1/20 0.43
FYN P06241 1/20 0.43
RET P07949 1/20 0.43
HCK P08631 1/20 0.43
PDGFRB P09619 1/20 0.43
PIM1 P11309 1/20 0.43
FGFR1 P11362 1/20 0.43
PDGFRA P16234 1/20 0.43
PRKCA P17252 1/20 0.43
PRKACA P17612 1/20 0.43
FLT1 P17948 1/20 0.43
FGFR2 P21802 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2303892 0.89 JAK2 (0.53) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL2302692 0.89 JAK2 (0.53) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL2303867 0.84 JAK2 (0.52) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL2306852 0.80 JAK2 (0.55) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL2303684 0.80 JAK2 (0.59) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL2307559 0.78 JAK2 (0.57) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL2305696 0.78 JAK2 (0.52) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL2303468 0.78 JAK2 (0.52) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL2306846 0.77 JAK2 (0.55) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL2307006 0.76 JAK2 (0.57) JAK2CHEK1JAK3JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005105814-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2005-11-10 WO claimed
WO-2013173506-A2 METHOD OF TREATING MUSCULAR DEGRADATION RIGEL PHARMACEUTICALS, INC. (US) 2013-11-21 WO disclosed